| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 263 | 2024 | 16715 | 8.800 |
Why?
|
| Anti-HIV Agents | 108 | 2024 | 4255 | 6.770 |
Why?
|
| Cost-Benefit Analysis | 146 | 2024 | 5390 | 4.500 |
Why?
|
| Anti-Retroviral Agents | 34 | 2023 | 1714 | 3.260 |
Why?
|
| AIDS-Related Opportunistic Infections | 41 | 2015 | 657 | 3.250 |
Why?
|
| Antiretroviral Therapy, Highly Active | 42 | 2019 | 1872 | 3.050 |
Why?
|
| CD4 Lymphocyte Count | 88 | 2021 | 2560 | 3.010 |
Why?
|
| Health Care Costs | 43 | 2022 | 3209 | 2.060 |
Why?
|
| Life Expectancy | 45 | 2023 | 1184 | 2.060 |
Why?
|
| Mass Screening | 40 | 2021 | 5255 | 2.030 |
Why?
|
| South Africa | 63 | 2023 | 1731 | 1.820 |
Why?
|
| Acquired Immunodeficiency Syndrome | 21 | 2022 | 2232 | 1.620 |
Why?
|
| Computer Simulation | 44 | 2022 | 6194 | 1.610 |
Why?
|
| Quality-Adjusted Life Years | 36 | 2023 | 1683 | 1.460 |
Why?
|
| Homosexuality, Male | 18 | 2024 | 1240 | 1.400 |
Why?
|
| Communicable Disease Control | 5 | 2022 | 857 | 1.280 |
Why?
|
| AIDS Serodiagnosis | 12 | 2016 | 184 | 1.250 |
Why?
|
| Infectious Disease Transmission, Vertical | 14 | 2023 | 1320 | 1.180 |
Why?
|
| Benzoxazines | 5 | 2019 | 301 | 1.110 |
Why?
|
| Tuberculosis | 16 | 2021 | 1912 | 1.040 |
Why?
|
| Chemoprevention | 8 | 2016 | 319 | 0.990 |
Why?
|
| Models, Economic | 15 | 2020 | 712 | 0.990 |
Why?
|
| Viral Load | 24 | 2019 | 3300 | 0.990 |
Why?
|
| HIV | 20 | 2023 | 1604 | 0.960 |
Why?
|
| Medication Adherence | 7 | 2020 | 2063 | 0.950 |
Why?
|
| HIV-1 | 29 | 2023 | 6939 | 0.940 |
Why?
|
| Drug Resistance, Viral | 12 | 2020 | 820 | 0.910 |
Why?
|
| Ambulatory Care Facilities | 9 | 2020 | 934 | 0.900 |
Why?
|
| Drug Monitoring | 6 | 2018 | 956 | 0.890 |
Why?
|
| Adult | 178 | 2023 | 214056 | 0.840 |
Why?
|
| Models, Theoretical | 21 | 2019 | 3589 | 0.830 |
Why?
|
| HIV Integrase Inhibitors | 3 | 2020 | 142 | 0.820 |
Why?
|
| RNA, Viral | 23 | 2018 | 2901 | 0.820 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 3 | 2019 | 215 | 0.810 |
Why?
|
| Drug Costs | 16 | 2020 | 1105 | 0.800 |
Why?
|
| Disease Transmission, Infectious | 5 | 2017 | 547 | 0.790 |
Why?
|
| Cote d'Ivoire | 16 | 2023 | 56 | 0.780 |
Why?
|
| Humans | 321 | 2024 | 744376 | 0.760 |
Why?
|
| Male | 186 | 2024 | 350118 | 0.750 |
Why?
|
| Developing Countries | 10 | 2022 | 2815 | 0.730 |
Why?
|
| Models, Biological | 23 | 2021 | 9584 | 0.730 |
Why?
|
| Drug Resistance, Multiple, Viral | 1 | 2020 | 52 | 0.720 |
Why?
|
| India | 11 | 2022 | 2197 | 0.710 |
Why?
|
| Patient Compliance | 10 | 2017 | 2685 | 0.700 |
Why?
|
| Mobile Health Units | 3 | 2015 | 80 | 0.680 |
Why?
|
| Nevirapine | 5 | 2015 | 267 | 0.680 |
Why?
|
| Female | 191 | 2024 | 380200 | 0.670 |
Why?
|
| Policy | 1 | 2022 | 508 | 0.640 |
Why?
|
| Health Resources | 8 | 2019 | 911 | 0.640 |
Why?
|
| Hepatitis B | 4 | 2024 | 695 | 0.610 |
Why?
|
| Cohort Studies | 52 | 2022 | 40558 | 0.590 |
Why?
|
| Antiviral Agents | 10 | 2024 | 2987 | 0.560 |
Why?
|
| Clinical Laboratory Techniques | 6 | 2020 | 738 | 0.560 |
Why?
|
| Nigeria | 8 | 2023 | 733 | 0.560 |
Why?
|
| Pneumonia, Pneumocystis | 6 | 2002 | 249 | 0.550 |
Why?
|
| Budgets | 5 | 2020 | 229 | 0.540 |
Why?
|
| Housing | 1 | 2020 | 664 | 0.540 |
Why?
|
| Adenine | 8 | 2020 | 936 | 0.530 |
Why?
|
| Point-of-Care Systems | 8 | 2019 | 1178 | 0.530 |
Why?
|
| Continuity of Patient Care | 10 | 2022 | 1049 | 0.520 |
Why?
|
| Drug Substitution | 1 | 2018 | 281 | 0.520 |
Why?
|
| Urban Health Services | 1 | 2016 | 179 | 0.520 |
Why?
|
| Universities | 1 | 2020 | 956 | 0.520 |
Why?
|
| Hepatitis C | 5 | 2019 | 1591 | 0.510 |
Why?
|
| United States | 72 | 2024 | 69869 | 0.510 |
Why?
|
| Models, Statistical | 13 | 2020 | 5101 | 0.500 |
Why?
|
| Antifungal Agents | 4 | 2017 | 729 | 0.490 |
Why?
|
| Hepatitis B, Chronic | 3 | 2024 | 393 | 0.490 |
Why?
|
| Hepatitis C, Chronic | 5 | 2015 | 1031 | 0.470 |
Why?
|
| Patient Acceptance of Health Care | 10 | 2016 | 3020 | 0.460 |
Why?
|
| Anti-Infective Agents | 7 | 2009 | 974 | 0.460 |
Why?
|
| Lost to Follow-Up | 5 | 2020 | 105 | 0.460 |
Why?
|
| Health Services Accessibility | 9 | 2017 | 5135 | 0.440 |
Why?
|
| Viremia | 1 | 2016 | 736 | 0.440 |
Why?
|
| Emigrants and Immigrants | 2 | 2016 | 522 | 0.430 |
Why?
|
| Glucuronosyltransferase | 1 | 2012 | 128 | 0.420 |
Why?
|
| Abnormalities, Drug-Induced | 2 | 2012 | 317 | 0.420 |
Why?
|
| Middle Aged | 82 | 2023 | 213388 | 0.410 |
Why?
|
| Office Visits | 1 | 2016 | 598 | 0.410 |
Why?
|
| Primary Health Care | 9 | 2017 | 4557 | 0.410 |
Why?
|
| Prevalence | 25 | 2022 | 15221 | 0.400 |
Why?
|
| Behavior Therapy | 2 | 2015 | 865 | 0.390 |
Why?
|
| Antibodies, Heterophile | 2 | 2001 | 126 | 0.390 |
Why?
|
| Infectious Mononucleosis | 2 | 2001 | 131 | 0.380 |
Why?
|
| Delivery of Health Care | 7 | 2021 | 5321 | 0.380 |
Why?
|
| HIV Protease Inhibitors | 4 | 2007 | 430 | 0.380 |
Why?
|
| Drugs, Generic | 5 | 2024 | 421 | 0.380 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2019 | 941 | 0.370 |
Why?
|
| Sensitivity and Specificity | 30 | 2021 | 14723 | 0.370 |
Why?
|
| Resource Allocation | 3 | 2009 | 341 | 0.370 |
Why?
|
| Decision Support Techniques | 12 | 2020 | 1956 | 0.360 |
Why?
|
| Microbial Sensitivity Tests | 5 | 2015 | 1877 | 0.360 |
Why?
|
| Genotype | 11 | 2020 | 12952 | 0.350 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 3 | 1999 | 76 | 0.350 |
Why?
|
| World Health Organization | 8 | 2014 | 1318 | 0.350 |
Why?
|
| Risk-Taking | 5 | 2013 | 986 | 0.350 |
Why?
|
| Bacteriological Techniques | 1 | 2010 | 277 | 0.340 |
Why?
|
| Ganciclovir | 2 | 2001 | 258 | 0.330 |
Why?
|
| Zimbabwe | 5 | 2022 | 129 | 0.330 |
Why?
|
| Substance Abuse, Intravenous | 4 | 2023 | 525 | 0.330 |
Why?
|
| Young Adult | 38 | 2024 | 56434 | 0.320 |
Why?
|
| Treatment Failure | 9 | 2017 | 2618 | 0.320 |
Why?
|
| Dementia | 1 | 2022 | 2518 | 0.310 |
Why?
|
| Alkynes | 5 | 2019 | 306 | 0.310 |
Why?
|
| Delayed Diagnosis | 1 | 2011 | 441 | 0.310 |
Why?
|
| Ribavirin | 5 | 2015 | 395 | 0.300 |
Why?
|
| State Health Plans | 3 | 2009 | 216 | 0.300 |
Why?
|
| Sputum | 8 | 2021 | 476 | 0.300 |
Why?
|
| Uterine Cervical Neoplasms | 3 | 2014 | 2020 | 0.300 |
Why?
|
| Cyclopropanes | 5 | 2019 | 416 | 0.300 |
Why?
|
| Drug Administration Schedule | 9 | 2020 | 4933 | 0.300 |
Why?
|
| Survival Analysis | 17 | 2019 | 10252 | 0.300 |
Why?
|
| HIV Seropositivity | 4 | 2013 | 971 | 0.300 |
Why?
|
| Patient-Centered Care | 1 | 2017 | 1438 | 0.290 |
Why?
|
| Lipopolysaccharides | 4 | 2021 | 2216 | 0.290 |
Why?
|
| Mycoses | 6 | 2007 | 376 | 0.290 |
Why?
|
| Africa South of the Sahara | 6 | 2021 | 724 | 0.290 |
Why?
|
| Mycobacterium tuberculosis | 4 | 2019 | 1832 | 0.290 |
Why?
|
| Tuberculosis, Pulmonary | 3 | 2019 | 810 | 0.280 |
Why?
|
| Quality Indicators, Health Care | 2 | 2017 | 1831 | 0.280 |
Why?
|
| Guidelines as Topic | 7 | 2017 | 1405 | 0.280 |
Why?
|
| Early Diagnosis | 9 | 2021 | 1184 | 0.280 |
Why?
|
| Cost of Illness | 8 | 2007 | 1860 | 0.280 |
Why?
|
| Pentamidine | 3 | 2002 | 45 | 0.270 |
Why?
|
| Treatment Outcome | 36 | 2020 | 63115 | 0.270 |
Why?
|
| Drug Therapy, Combination | 11 | 2012 | 6489 | 0.270 |
Why?
|
| Motivation | 1 | 2015 | 1971 | 0.270 |
Why?
|
| Secondary Prevention | 1 | 2012 | 1530 | 0.270 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 3242 | 0.260 |
Why?
|
| Community Health Services | 3 | 2018 | 650 | 0.260 |
Why?
|
| Brazil | 4 | 2024 | 1270 | 0.260 |
Why?
|
| Lamivudine | 2 | 2017 | 342 | 0.260 |
Why?
|
| Medical Assistance | 2 | 2002 | 104 | 0.250 |
Why?
|
| Cytomegalovirus Infections | 4 | 2002 | 820 | 0.250 |
Why?
|
| Markov Chains | 11 | 2015 | 969 | 0.250 |
Why?
|
| Adolescent | 41 | 2024 | 85784 | 0.250 |
Why?
|
| Diagnostic Tests, Routine | 5 | 2021 | 783 | 0.250 |
Why?
|
| Immunotherapy, Active | 1 | 2004 | 60 | 0.250 |
Why?
|
| Monte Carlo Method | 6 | 2019 | 1254 | 0.250 |
Why?
|
| AIDS Vaccines | 2 | 2016 | 938 | 0.240 |
Why?
|
| Time Factors | 22 | 2018 | 40077 | 0.240 |
Why?
|
| Ritonavir | 4 | 2015 | 322 | 0.240 |
Why?
|
| Public Sector | 3 | 2019 | 265 | 0.240 |
Why?
|
| Public Health | 5 | 2020 | 2602 | 0.240 |
Why?
|
| Dapsone | 2 | 2002 | 54 | 0.230 |
Why?
|
| Hospitalization | 4 | 2021 | 10259 | 0.230 |
Why?
|
| Public Health Administration | 1 | 2006 | 240 | 0.230 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2012 | 1164 | 0.230 |
Why?
|
| Clinical Trials as Topic | 10 | 2023 | 7914 | 0.220 |
Why?
|
| Kenya | 3 | 2022 | 685 | 0.220 |
Why?
|
| Antibodies, Monoclonal | 1 | 2020 | 9274 | 0.220 |
Why?
|
| Voluntary Programs | 4 | 2011 | 42 | 0.220 |
Why?
|
| Financing, Government | 1 | 2006 | 468 | 0.210 |
Why?
|
| Program Evaluation | 6 | 2015 | 2488 | 0.210 |
Why?
|
| Practice Guidelines as Topic | 7 | 2012 | 7281 | 0.210 |
Why?
|
| Genetic Testing | 2 | 2012 | 3444 | 0.210 |
Why?
|
| Boston | 11 | 2010 | 9312 | 0.210 |
Why?
|
| Depression | 3 | 2023 | 7766 | 0.210 |
Why?
|
| Oxazines | 3 | 2019 | 298 | 0.210 |
Why?
|
| Naphthoquinones | 1 | 2002 | 77 | 0.210 |
Why?
|
| Risk Factors | 30 | 2018 | 72295 | 0.210 |
Why?
|
| Smoking Cessation | 3 | 2020 | 2071 | 0.210 |
Why?
|
| CD4-Positive T-Lymphocytes | 6 | 2013 | 4386 | 0.200 |
Why?
|
| Infant | 18 | 2023 | 35134 | 0.200 |
Why?
|
| Incidence | 16 | 2022 | 20950 | 0.200 |
Why?
|
| Patient Dropouts | 2 | 2020 | 421 | 0.200 |
Why?
|
| Antiprotozoal Agents | 1 | 2002 | 86 | 0.200 |
Why?
|
| France | 6 | 2012 | 517 | 0.200 |
Why?
|
| Reverse Transcriptase Inhibitors | 6 | 2020 | 615 | 0.200 |
Why?
|
| Community Health Centers | 3 | 2021 | 430 | 0.200 |
Why?
|
| Alcohol-Related Disorders | 1 | 2004 | 234 | 0.200 |
Why?
|
| Europe | 3 | 2023 | 3339 | 0.190 |
Why?
|
| Thyroiditis | 1 | 2001 | 85 | 0.190 |
Why?
|
| Patient Simulation | 2 | 2020 | 309 | 0.190 |
Why?
|
| Preventive Health Services | 1 | 2006 | 575 | 0.190 |
Why?
|
| Forecasting | 4 | 2020 | 2951 | 0.180 |
Why?
|
| Antibodies, Viral | 3 | 2020 | 3177 | 0.180 |
Why?
|
| Models, Econometric | 4 | 2007 | 218 | 0.180 |
Why?
|
| Outpatient Clinics, Hospital | 4 | 2007 | 392 | 0.180 |
Why?
|
| Breast Feeding | 4 | 2018 | 1338 | 0.180 |
Why?
|
| Massachusetts | 9 | 2023 | 8662 | 0.180 |
Why?
|
| Pregnancy | 19 | 2024 | 29144 | 0.180 |
Why?
|
| Disease Progression | 15 | 2015 | 13285 | 0.180 |
Why?
|
| Alcoholism | 3 | 2005 | 1906 | 0.180 |
Why?
|
| Iodide Peroxidase | 1 | 2001 | 293 | 0.180 |
Why?
|
| Direct Service Costs | 3 | 2006 | 62 | 0.170 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2002 | 336 | 0.170 |
Why?
|
| Fees and Charges | 1 | 2020 | 195 | 0.170 |
Why?
|
| Herpesvirus 4, Human | 2 | 2001 | 1041 | 0.170 |
Why?
|
| Sarcoma, Kaposi | 1 | 2022 | 370 | 0.170 |
Why?
|
| Interferons | 2 | 2014 | 706 | 0.170 |
Why?
|
| Quality of Life | 17 | 2019 | 12803 | 0.170 |
Why?
|
| Health Knowledge, Attitudes, Practice | 5 | 2019 | 3922 | 0.170 |
Why?
|
| Cause of Death | 3 | 2017 | 3582 | 0.170 |
Why?
|
| Pyridones | 3 | 2019 | 712 | 0.170 |
Why?
|
| Botswana | 1 | 2022 | 1040 | 0.160 |
Why?
|
| Dideoxynucleosides | 2 | 2017 | 122 | 0.160 |
Why?
|
| Regression Analysis | 7 | 2016 | 6459 | 0.160 |
Why?
|
| Masks | 1 | 2020 | 197 | 0.160 |
Why?
|
| Infant, Newborn | 13 | 2024 | 25628 | 0.160 |
Why?
|
| Colposcopy | 1 | 1999 | 144 | 0.160 |
Why?
|
| HLA-B Antigens | 2 | 2010 | 354 | 0.160 |
Why?
|
| Serologic Tests | 1 | 2020 | 374 | 0.160 |
Why?
|
| Infant Care | 1 | 2019 | 183 | 0.160 |
Why?
|
| Asymptomatic Infections | 1 | 2019 | 128 | 0.160 |
Why?
|
| Protease Inhibitors | 2 | 2012 | 791 | 0.160 |
Why?
|
| National Health Programs | 2 | 2019 | 445 | 0.150 |
Why?
|
| Thyrotropin | 1 | 2001 | 849 | 0.150 |
Why?
|
| Outpatients | 5 | 2018 | 1487 | 0.150 |
Why?
|
| Postnatal Care | 1 | 2019 | 236 | 0.150 |
Why?
|
| Smoking | 4 | 2020 | 8987 | 0.150 |
Why?
|
| Nystatin | 1 | 2017 | 23 | 0.150 |
Why?
|
| Zidovudine | 4 | 2015 | 620 | 0.150 |
Why?
|
| Fluconazole | 1 | 1997 | 146 | 0.150 |
Why?
|
| HIV Seroprevalence | 2 | 2011 | 86 | 0.150 |
Why?
|
| Gentian Violet | 1 | 2017 | 31 | 0.150 |
Why?
|
| Candidiasis, Oral | 1 | 2017 | 60 | 0.150 |
Why?
|
| Public Health Practice | 1 | 2019 | 218 | 0.140 |
Why?
|
| Urban Population | 5 | 2017 | 2022 | 0.140 |
Why?
|
| Cultural Competency | 1 | 2019 | 289 | 0.140 |
Why?
|
| Observation | 1 | 2017 | 312 | 0.130 |
Why?
|
| Vaginal Smears | 1 | 1999 | 511 | 0.130 |
Why?
|
| Demography | 4 | 2015 | 1656 | 0.130 |
Why?
|
| Patents as Topic | 1 | 2016 | 103 | 0.130 |
Why?
|
| HIV Fusion Inhibitors | 2 | 2006 | 81 | 0.130 |
Why?
|
| Medically Uninsured | 1 | 2001 | 853 | 0.130 |
Why?
|
| Comprehensive Health Care | 1 | 2016 | 127 | 0.130 |
Why?
|
| Cryptococcus | 1 | 2015 | 29 | 0.130 |
Why?
|
| Hepatitis B virus | 3 | 2024 | 513 | 0.130 |
Why?
|
| Malnutrition | 2 | 2014 | 625 | 0.130 |
Why?
|
| Research Personnel | 1 | 2020 | 573 | 0.130 |
Why?
|
| Pneumocystis | 1 | 1995 | 57 | 0.130 |
Why?
|
| Counseling | 5 | 2013 | 1523 | 0.130 |
Why?
|
| Child | 20 | 2023 | 77708 | 0.130 |
Why?
|
| Antigens, Fungal | 1 | 2015 | 70 | 0.130 |
Why?
|
| Melanoma | 2 | 2007 | 5511 | 0.130 |
Why?
|
| Africa | 2 | 2014 | 672 | 0.130 |
Why?
|
| Circumcision, Male | 1 | 2016 | 150 | 0.130 |
Why?
|
| Government Programs | 2 | 2007 | 275 | 0.130 |
Why?
|
| Uridine Monophosphate | 1 | 2015 | 70 | 0.130 |
Why?
|
| Pregnancy Complications, Infectious | 6 | 2021 | 2026 | 0.130 |
Why?
|
| Statistics, Nonparametric | 2 | 2016 | 2887 | 0.120 |
Why?
|
| Poverty | 1 | 2006 | 2660 | 0.120 |
Why?
|
| Epidemics | 1 | 2020 | 523 | 0.120 |
Why?
|
| Retrospective Studies | 16 | 2021 | 77459 | 0.120 |
Why?
|
| Delayed-Action Preparations | 2 | 2015 | 968 | 0.120 |
Why?
|
| Inpatients | 2 | 2006 | 2518 | 0.120 |
Why?
|
| Rural Population | 4 | 2018 | 2207 | 0.120 |
Why?
|
| Cryptococcosis | 1 | 2015 | 101 | 0.120 |
Why?
|
| Sexual Behavior | 7 | 2024 | 2055 | 0.120 |
Why?
|
| Liver Function Tests | 2 | 2012 | 528 | 0.120 |
Why?
|
| Health Education | 1 | 2001 | 1056 | 0.120 |
Why?
|
| Drug Combinations | 2 | 2017 | 1958 | 0.120 |
Why?
|
| Prenatal Diagnosis | 1 | 2001 | 1236 | 0.120 |
Why?
|
| Condoms | 1 | 2016 | 323 | 0.120 |
Why?
|
| Alcohol Drinking | 3 | 2004 | 3966 | 0.120 |
Why?
|
| Skin Neoplasms | 2 | 2007 | 5692 | 0.120 |
Why?
|
| Mycobacterium Infections | 2 | 2006 | 119 | 0.120 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 2 | 2012 | 912 | 0.120 |
Why?
|
| Pyrrolidinones | 1 | 2014 | 117 | 0.120 |
Why?
|
| HIV Envelope Protein gp41 | 2 | 2006 | 314 | 0.120 |
Why?
|
| Child, Preschool | 9 | 2022 | 41005 | 0.120 |
Why?
|
| Epidemiologic Research Design | 1 | 2017 | 367 | 0.120 |
Why?
|
| Patients | 1 | 2020 | 900 | 0.110 |
Why?
|
| Gross Domestic Product | 1 | 2013 | 77 | 0.110 |
Why?
|
| Stavudine | 2 | 2010 | 85 | 0.110 |
Why?
|
| Medically Underserved Area | 1 | 2015 | 253 | 0.110 |
Why?
|
| Risk Assessment | 8 | 2022 | 23336 | 0.110 |
Why?
|
| Geographic Information Systems | 1 | 2015 | 281 | 0.110 |
Why?
|
| Antibodies | 1 | 2001 | 2460 | 0.110 |
Why?
|
| Piperazines | 3 | 2019 | 2488 | 0.110 |
Why?
|
| Hepatitis B e Antigens | 2 | 2024 | 133 | 0.110 |
Why?
|
| Infant Mortality | 1 | 2018 | 754 | 0.110 |
Why?
|
| HIV Antibodies | 4 | 2023 | 1322 | 0.110 |
Why?
|
| Decision Making | 5 | 2020 | 3888 | 0.110 |
Why?
|
| Prospective Studies | 16 | 2023 | 53291 | 0.110 |
Why?
|
| Interprofessional Relations | 1 | 2019 | 1011 | 0.110 |
Why?
|
| Liver Cirrhosis | 3 | 2024 | 1862 | 0.110 |
Why?
|
| Physician's Role | 1 | 1999 | 943 | 0.110 |
Why?
|
| HIV Reverse Transcriptase | 3 | 2009 | 213 | 0.110 |
Why?
|
| Decision Trees | 5 | 2009 | 506 | 0.100 |
Why?
|
| Interferon-alpha | 4 | 2015 | 895 | 0.100 |
Why?
|
| Patient Transfer | 1 | 2019 | 762 | 0.100 |
Why?
|
| Self Care | 1 | 2017 | 786 | 0.100 |
Why?
|
| Hepatitis C Antibodies | 1 | 2012 | 145 | 0.100 |
Why?
|
| Antigen Presentation | 2 | 2010 | 1284 | 0.100 |
Why?
|
| Cardiovascular Diseases | 2 | 2017 | 15159 | 0.100 |
Why?
|
| Hepacivirus | 2 | 2017 | 1379 | 0.100 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2019 | 1035 | 0.100 |
Why?
|
| Patient Participation | 1 | 2001 | 1457 | 0.100 |
Why?
|
| Geography | 2 | 2013 | 669 | 0.100 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2024 | 2214 | 0.100 |
Why?
|
| Pandemics | 5 | 2024 | 8386 | 0.100 |
Why?
|
| Vaccination | 2 | 2022 | 3279 | 0.100 |
Why?
|
| Treatment Refusal | 2 | 2006 | 421 | 0.100 |
Why?
|
| Specialization | 1 | 2016 | 776 | 0.100 |
Why?
|
| Recurrence | 4 | 2020 | 8340 | 0.100 |
Why?
|
| State Government | 2 | 2006 | 372 | 0.100 |
Why?
|
| Bacterial Infections | 4 | 2007 | 1401 | 0.100 |
Why?
|
| Pyrimidinones | 2 | 2011 | 371 | 0.100 |
Why?
|
| International Cooperation | 1 | 2017 | 1420 | 0.090 |
Why?
|
| Tuberculin Test | 1 | 2011 | 214 | 0.090 |
Why?
|
| Microscopy | 2 | 2019 | 902 | 0.090 |
Why?
|
| Skin Diseases | 1 | 1999 | 1066 | 0.090 |
Why?
|
| Teratogens | 1 | 2011 | 112 | 0.090 |
Why?
|
| Candidiasis | 2 | 2008 | 366 | 0.090 |
Why?
|
| Quality Improvement | 2 | 2017 | 3749 | 0.090 |
Why?
|
| Genes, MHC Class I | 1 | 2010 | 258 | 0.090 |
Why?
|
| Pharmacogenetics | 2 | 2011 | 674 | 0.090 |
Why?
|
| Reminder Systems | 1 | 2012 | 371 | 0.090 |
Why?
|
| Public Assistance | 1 | 2009 | 47 | 0.090 |
Why?
|
| False Positive Reactions | 3 | 2020 | 980 | 0.090 |
Why?
|
| Patient Selection | 1 | 2001 | 4216 | 0.080 |
Why?
|
| Cross-Sectional Studies | 7 | 2019 | 25041 | 0.080 |
Why?
|
| Systems Integration | 1 | 2011 | 440 | 0.080 |
Why?
|
| Appointments and Schedules | 1 | 2012 | 417 | 0.080 |
Why?
|
| Multivariate Analysis | 7 | 2018 | 12244 | 0.080 |
Why?
|
| Primary Prevention | 1 | 2016 | 1167 | 0.080 |
Why?
|
| Follow-Up Studies | 12 | 2019 | 39052 | 0.080 |
Why?
|
| Survival Rate | 3 | 2012 | 12788 | 0.080 |
Why?
|
| Age Distribution | 2 | 2023 | 2902 | 0.080 |
Why?
|
| Self Report | 2 | 2017 | 3557 | 0.080 |
Why?
|
| Latent Tuberculosis | 1 | 2011 | 225 | 0.080 |
Why?
|
| Sentinel Surveillance | 2 | 2007 | 281 | 0.080 |
Why?
|
| Immunoassay | 1 | 2012 | 752 | 0.080 |
Why?
|
| Health Policy | 4 | 2019 | 2661 | 0.080 |
Why?
|
| Oligopeptides | 1 | 2014 | 1189 | 0.080 |
Why?
|
| Methotrexate | 1 | 1995 | 1728 | 0.080 |
Why?
|
| Diagnostic Services | 1 | 2007 | 34 | 0.080 |
Why?
|
| HIV Antigens | 2 | 2010 | 347 | 0.080 |
Why?
|
| Value of Life | 2 | 2001 | 97 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 3 | 2010 | 6171 | 0.080 |
Why?
|
| Data Collection | 3 | 2011 | 3339 | 0.080 |
Why?
|
| DNA, Viral | 3 | 2024 | 2227 | 0.080 |
Why?
|
| Liver Neoplasms | 1 | 2024 | 4253 | 0.080 |
Why?
|
| Logistic Models | 5 | 2018 | 13409 | 0.080 |
Why?
|
| Hemoglobins, Abnormal | 1 | 2008 | 119 | 0.080 |
Why?
|
| Health Services Research | 1 | 2015 | 1836 | 0.080 |
Why?
|
| Health Expenditures | 1 | 2020 | 2349 | 0.080 |
Why?
|
| Meningitis, Cryptococcal | 1 | 2008 | 63 | 0.080 |
Why?
|
| Health Care Rationing | 3 | 2017 | 437 | 0.070 |
Why?
|
| Medical Informatics | 1 | 2014 | 745 | 0.070 |
Why?
|
| Toxoplasmosis, Cerebral | 1 | 2006 | 18 | 0.070 |
Why?
|
| Telemedicine | 1 | 2024 | 2872 | 0.070 |
Why?
|
| Mozambique | 2 | 2017 | 54 | 0.070 |
Why?
|
| Aged | 16 | 2020 | 163284 | 0.070 |
Why?
|
| Staining and Labeling | 1 | 2010 | 1101 | 0.070 |
Why?
|
| Public Policy | 1 | 2010 | 572 | 0.070 |
Why?
|
| Anus Neoplasms | 2 | 2000 | 332 | 0.070 |
Why?
|
| Stem Cell Transplantation | 1 | 2014 | 1620 | 0.070 |
Why?
|
| Hospitals, Municipal | 2 | 1995 | 19 | 0.070 |
Why?
|
| DNA, Bacterial | 1 | 2010 | 1465 | 0.070 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2006 | 199 | 0.070 |
Why?
|
| Internationality | 1 | 2011 | 1002 | 0.060 |
Why?
|
| Self Disclosure | 1 | 2006 | 251 | 0.060 |
Why?
|
| Drug Therapy | 2 | 2020 | 497 | 0.060 |
Why?
|
| Calibration | 2 | 2020 | 816 | 0.060 |
Why?
|
| Disclosure | 2 | 2023 | 736 | 0.060 |
Why?
|
| Drug Utilization | 1 | 2011 | 1183 | 0.060 |
Why?
|
| Referral and Consultation | 3 | 2012 | 3529 | 0.060 |
Why?
|
| Sulfonamides | 1 | 2014 | 1940 | 0.060 |
Why?
|
| Private Sector | 1 | 2007 | 392 | 0.060 |
Why?
|
| Antitubercular Agents | 3 | 2020 | 1320 | 0.060 |
Why?
|
| Federal Government | 1 | 2006 | 260 | 0.060 |
Why?
|
| Rifampin | 2 | 2019 | 315 | 0.060 |
Why?
|
| Health Behavior | 2 | 2012 | 2635 | 0.060 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2006 | 214 | 0.060 |
Why?
|
| Opioid-Related Disorders | 1 | 2019 | 2064 | 0.060 |
Why?
|
| Longitudinal Studies | 3 | 2010 | 13988 | 0.060 |
Why?
|
| Needlestick Injuries | 1 | 2004 | 67 | 0.060 |
Why?
|
| Group Homes | 1 | 2023 | 34 | 0.060 |
Why?
|
| Internal Medicine | 1 | 2011 | 1009 | 0.060 |
Why?
|
| HLA Antigens | 1 | 2009 | 1382 | 0.060 |
Why?
|
| Predictive Value of Tests | 5 | 2011 | 15078 | 0.060 |
Why?
|
| Mental Disorders | 1 | 2023 | 6600 | 0.060 |
Why?
|
| Gene Products, gag | 1 | 2004 | 337 | 0.060 |
Why?
|
| Drug Discovery | 1 | 2012 | 1058 | 0.060 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2010 | 1205 | 0.060 |
Why?
|
| Registries | 2 | 2016 | 8091 | 0.060 |
Why?
|
| Ambulatory Care | 4 | 2011 | 2708 | 0.060 |
Why?
|
| Prisoners | 1 | 2006 | 297 | 0.060 |
Why?
|
| Heterosexuality | 2 | 2016 | 276 | 0.060 |
Why?
|
| Ukraine | 1 | 2023 | 111 | 0.060 |
Why?
|
| Peptide Fragments | 2 | 2006 | 5096 | 0.060 |
Why?
|
| Odds Ratio | 4 | 2013 | 9849 | 0.060 |
Why?
|
| Prognosis | 3 | 2019 | 29060 | 0.060 |
Why?
|
| Toxoplasmosis | 2 | 2007 | 91 | 0.060 |
Why?
|
| Pneumonia | 1 | 1995 | 2133 | 0.060 |
Why?
|
| Biopsy | 1 | 1995 | 6755 | 0.050 |
Why?
|
| Chickenpox | 1 | 2003 | 131 | 0.050 |
Why?
|
| Parasitic Diseases | 1 | 2003 | 75 | 0.050 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2024 | 305 | 0.050 |
Why?
|
| Analgesics, Opioid | 1 | 2019 | 3677 | 0.050 |
Why?
|
| Ethambutol | 2 | 2012 | 60 | 0.050 |
Why?
|
| Atovaquone | 1 | 2002 | 58 | 0.050 |
Why?
|
| Siblings | 1 | 2007 | 854 | 0.050 |
Why?
|
| HIV Long-Term Survivors | 3 | 2010 | 126 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3135 | 0.050 |
Why?
|
| Polyethylene Glycols | 1 | 2008 | 1182 | 0.050 |
Why?
|
| Lead Poisoning | 2 | 1995 | 301 | 0.050 |
Why?
|
| Social Stigma | 2 | 2023 | 701 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 6539 | 0.050 |
Why?
|
| Statistics as Topic | 1 | 2008 | 2373 | 0.050 |
Why?
|
| Risk | 4 | 2015 | 9688 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2006 | 1677 | 0.050 |
Why?
|
| Bleomycin | 1 | 2022 | 512 | 0.050 |
Why?
|
| Health Services | 1 | 2006 | 758 | 0.050 |
Why?
|
| Bisexuality | 2 | 2000 | 269 | 0.050 |
Why?
|
| Hospitals | 2 | 2017 | 3954 | 0.050 |
Why?
|
| Biomedical Research | 1 | 2016 | 3309 | 0.050 |
Why?
|
| Age Factors | 2 | 2016 | 18373 | 0.050 |
Why?
|
| Pharmaceutical Services | 1 | 2002 | 140 | 0.050 |
Why?
|
| Sex Distribution | 1 | 2006 | 2297 | 0.050 |
Why?
|
| Algorithms | 4 | 2014 | 13882 | 0.050 |
Why?
|
| Etoposide | 1 | 2022 | 641 | 0.050 |
Why?
|
| Physicians | 1 | 2019 | 4567 | 0.050 |
Why?
|
| Financial Management | 1 | 2002 | 160 | 0.050 |
Why?
|
| Insurance Coverage | 2 | 2002 | 1900 | 0.050 |
Why?
|
| Isoniazid | 2 | 2012 | 274 | 0.050 |
Why?
|
| Morbidity | 3 | 2012 | 1768 | 0.050 |
Why?
|
| Data Interpretation, Statistical | 2 | 2017 | 2716 | 0.050 |
Why?
|
| Reproducibility of Results | 7 | 2014 | 19905 | 0.050 |
Why?
|
| Disabled Persons | 1 | 2010 | 1212 | 0.050 |
Why?
|
| Florida | 1 | 2001 | 435 | 0.050 |
Why?
|
| Vincristine | 1 | 2022 | 1039 | 0.050 |
Why?
|
| Anonymous Testing | 1 | 1999 | 8 | 0.050 |
Why?
|
| Patient Satisfaction | 1 | 2012 | 3395 | 0.050 |
Why?
|
| Leukoplakia, Hairy | 1 | 1999 | 8 | 0.040 |
Why?
|
| Medicaid | 2 | 2005 | 2737 | 0.040 |
Why?
|
| Mortality | 3 | 2019 | 2864 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2006 | 1534 | 0.040 |
Why?
|
| Health Status Indicators | 2 | 2003 | 970 | 0.040 |
Why?
|
| Cost Savings | 3 | 2015 | 925 | 0.040 |
Why?
|
| Malaria | 2 | 2007 | 1239 | 0.040 |
Why?
|
| Folliculitis | 1 | 1999 | 28 | 0.040 |
Why?
|
| Proportional Hazards Models | 4 | 2011 | 12356 | 0.040 |
Why?
|
| Amino Acid Substitution | 1 | 2004 | 1793 | 0.040 |
Why?
|
| Substance-Related Disorders | 2 | 2015 | 4257 | 0.040 |
Why?
|
| Dermatomycoses | 1 | 1999 | 45 | 0.040 |
Why?
|
| Arthritis, Rheumatoid | 1 | 1995 | 3712 | 0.040 |
Why?
|
| HIV Seronegativity | 1 | 2000 | 211 | 0.040 |
Why?
|
| Liver | 1 | 1995 | 7475 | 0.040 |
Why?
|
| Rifabutin | 1 | 1999 | 52 | 0.040 |
Why?
|
| Drugs, Investigational | 1 | 2001 | 214 | 0.040 |
Why?
|
| New York | 1 | 2001 | 886 | 0.040 |
Why?
|
| Los Angeles | 1 | 2019 | 238 | 0.040 |
Why?
|
| Haiti | 2 | 2014 | 553 | 0.040 |
Why?
|
| Organizational Innovation | 1 | 2002 | 559 | 0.040 |
Why?
|
| Seroepidemiologic Studies | 1 | 2020 | 402 | 0.040 |
Why?
|
| Clarithromycin | 1 | 1999 | 86 | 0.040 |
Why?
|
| Organizations | 1 | 2019 | 170 | 0.040 |
Why?
|
| Eligibility Determination | 1 | 2002 | 403 | 0.040 |
Why?
|
| Tumor Virus Infections | 1 | 2001 | 454 | 0.040 |
Why?
|
| Alanine | 1 | 2020 | 572 | 0.040 |
Why?
|
| Administration, Oral | 2 | 2017 | 3914 | 0.040 |
Why?
|
| Ethics | 1 | 1998 | 94 | 0.040 |
Why?
|
| Malawi | 1 | 2019 | 282 | 0.040 |
Why?
|
| Canada | 1 | 2023 | 2065 | 0.040 |
Why?
|
| History, 20th Century | 1 | 2006 | 2740 | 0.040 |
Why?
|
| Drug Resistance, Microbial | 1 | 2001 | 862 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2008 | 2759 | 0.040 |
Why?
|
| Leukocyte Count | 2 | 1992 | 1588 | 0.040 |
Why?
|
| Intention | 1 | 2020 | 342 | 0.040 |
Why?
|
| Azithromycin | 1 | 1999 | 196 | 0.040 |
Why?
|
| Developed Countries | 2 | 2012 | 437 | 0.040 |
Why?
|
| RNA, Messenger | 1 | 2012 | 13035 | 0.040 |
Why?
|
| Electronic Health Records | 1 | 2014 | 4468 | 0.040 |
Why?
|
| Efficiency, Organizational | 1 | 2002 | 695 | 0.040 |
Why?
|
| Hospitals, Teaching | 1 | 2002 | 1180 | 0.040 |
Why?
|
| Aged, 80 and over | 6 | 2020 | 57776 | 0.040 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2004 | 1821 | 0.040 |
Why?
|
| Chi-Square Distribution | 2 | 2001 | 3508 | 0.040 |
Why?
|
| Probability | 2 | 2005 | 2506 | 0.040 |
Why?
|
| Neural Tube Defects | 1 | 2019 | 256 | 0.040 |
Why?
|
| Deoxycytidine | 2 | 2013 | 826 | 0.040 |
Why?
|
| Viral Proteins | 1 | 2004 | 1900 | 0.040 |
Why?
|
| Pediatrics | 1 | 2012 | 3475 | 0.040 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2019 | 323 | 0.040 |
Why?
|
| Nutrition Surveys | 1 | 2023 | 1660 | 0.040 |
Why?
|
| Cytomegalovirus | 1 | 2001 | 733 | 0.030 |
Why?
|
| Immunoglobulin M | 1 | 2001 | 1537 | 0.030 |
Why?
|
| Systems Analysis | 1 | 2017 | 172 | 0.030 |
Why?
|
| Nursing Homes | 1 | 2023 | 1036 | 0.030 |
Why?
|
| Immunization | 1 | 2021 | 1256 | 0.030 |
Why?
|
| Occupational Diseases | 1 | 2004 | 1469 | 0.030 |
Why?
|
| Child, Orphaned | 1 | 2016 | 55 | 0.030 |
Why?
|
| Dermatology | 1 | 2006 | 872 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2001 | 4034 | 0.030 |
Why?
|
| Protozoan Infections | 1 | 1995 | 39 | 0.030 |
Why?
|
| Sex Factors | 1 | 2009 | 10400 | 0.030 |
Why?
|
| Diet | 1 | 2014 | 7937 | 0.030 |
Why?
|
| Costs and Cost Analysis | 2 | 2011 | 1680 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2006 | 2616 | 0.030 |
Why?
|
| Evolution, Molecular | 1 | 2004 | 1939 | 0.030 |
Why?
|
| Chronic Disease | 2 | 2011 | 9145 | 0.030 |
Why?
|
| Cytodiagnosis | 1 | 1999 | 435 | 0.030 |
Why?
|
| Nicotine | 1 | 2020 | 681 | 0.030 |
Why?
|
| Opiate Substitution Treatment | 1 | 2019 | 404 | 0.030 |
Why?
|
| Papillomaviridae | 1 | 2001 | 1119 | 0.030 |
Why?
|
| Urban Health | 2 | 2008 | 547 | 0.030 |
Why?
|
| Administration, Topical | 1 | 2017 | 690 | 0.030 |
Why?
|
| Postpartum Period | 1 | 2001 | 1086 | 0.030 |
Why?
|
| Chelation Therapy | 1 | 1995 | 66 | 0.030 |
Why?
|
| Paclitaxel | 1 | 2022 | 1708 | 0.030 |
Why?
|
| Internship and Residency | 2 | 2011 | 5789 | 0.030 |
Why?
|
| Edetic Acid | 1 | 1995 | 275 | 0.030 |
Why?
|
| Africa, Eastern | 1 | 2014 | 71 | 0.030 |
Why?
|
| Clinical Protocols | 2 | 2009 | 1462 | 0.030 |
Why?
|
| Focus Groups | 1 | 2019 | 1321 | 0.030 |
Why?
|
| Homosexuality | 2 | 2009 | 262 | 0.030 |
Why?
|
| Blood Proteins | 1 | 1979 | 1124 | 0.030 |
Why?
|
| Fees, Medical | 1 | 1994 | 117 | 0.030 |
Why?
|
| Portugal | 1 | 2013 | 87 | 0.030 |
Why?
|
| Prenatal Care | 1 | 2001 | 1092 | 0.030 |
Why?
|
| Electrolytes | 1 | 1994 | 282 | 0.030 |
Why?
|
| Truth Disclosure | 1 | 1998 | 436 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2003 | 3420 | 0.030 |
Why?
|
| Cholesterol | 1 | 2002 | 2919 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2017 | 13104 | 0.030 |
Why?
|
| Health Status | 2 | 2003 | 4033 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2017 | 1591 | 0.030 |
Why?
|
| Streptomycin | 1 | 2012 | 69 | 0.030 |
Why?
|
| Kanamycin | 1 | 2012 | 64 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2005 | 8319 | 0.030 |
Why?
|
| Therapy, Computer-Assisted | 1 | 1995 | 274 | 0.030 |
Why?
|
| Perception | 1 | 2019 | 1198 | 0.030 |
Why?
|
| Blood Specimen Collection | 1 | 1994 | 246 | 0.030 |
Why?
|
| Precancerous Conditions | 1 | 1999 | 975 | 0.030 |
Why?
|
| Recombinant Proteins | 3 | 2008 | 6621 | 0.030 |
Why?
|
| Patient Preference | 1 | 2019 | 889 | 0.030 |
Why?
|
| National Institute of Allergy and Infectious Diseases (U.S.) | 1 | 2011 | 62 | 0.030 |
Why?
|
| Exercise Test | 1 | 1999 | 2073 | 0.030 |
Why?
|
| Models, Organizational | 1 | 1995 | 574 | 0.030 |
Why?
|
| Urinalysis | 1 | 2014 | 369 | 0.030 |
Why?
|
| Infection Control | 1 | 2019 | 965 | 0.020 |
Why?
|
| Confidence Intervals | 2 | 2010 | 2971 | 0.020 |
Why?
|
| Research Design | 2 | 2020 | 5986 | 0.020 |
Why?
|
| Blood Gas Analysis | 1 | 1992 | 383 | 0.020 |
Why?
|
| Hospitals, Rural | 1 | 2012 | 172 | 0.020 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 1994 | 397 | 0.020 |
Why?
|
| Analysis of Variance | 3 | 2013 | 6366 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2010 | 7658 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2012 | 4751 | 0.020 |
Why?
|
| Causality | 1 | 2017 | 1275 | 0.020 |
Why?
|
| Social Support | 2 | 2017 | 2118 | 0.020 |
Why?
|
| Hospitals, Urban | 1 | 2012 | 499 | 0.020 |
Why?
|
| Sickness Impact Profile | 1 | 2012 | 302 | 0.020 |
Why?
|
| HLA-C Antigens | 1 | 2010 | 147 | 0.020 |
Why?
|
| Family Characteristics | 1 | 2015 | 1000 | 0.020 |
Why?
|
| District of Columbia | 1 | 2010 | 157 | 0.020 |
Why?
|
| Reference Standards | 1 | 2014 | 1025 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2019 | 2682 | 0.020 |
Why?
|
| Medical Staff, Hospital | 1 | 1994 | 601 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2010 | 3873 | 0.020 |
Why?
|
| HLA-A Antigens | 1 | 2010 | 232 | 0.020 |
Why?
|
| Vulnerable Populations | 1 | 2015 | 686 | 0.020 |
Why?
|
| CD4-CD8 Ratio | 1 | 2009 | 112 | 0.020 |
Why?
|
| Sexual Partners | 1 | 2014 | 729 | 0.020 |
Why?
|
| Drug Administration Routes | 1 | 2010 | 153 | 0.020 |
Why?
|
| False Negative Reactions | 1 | 2011 | 588 | 0.020 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2011 | 224 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2017 | 2453 | 0.020 |
Why?
|
| Papillomavirus Infections | 1 | 2001 | 1587 | 0.020 |
Why?
|
| Family | 1 | 2020 | 3147 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2001 | 4561 | 0.020 |
Why?
|
| Clinical Trials, Phase IV as Topic | 1 | 2009 | 27 | 0.020 |
Why?
|
| Virus Diseases | 1 | 1995 | 711 | 0.020 |
Why?
|
| Data Mining | 1 | 2014 | 537 | 0.020 |
Why?
|
| Drug Tolerance | 1 | 1991 | 376 | 0.020 |
Why?
|
| Contact Tracing | 1 | 2011 | 273 | 0.020 |
Why?
|
| Hospitals, University | 1 | 2011 | 570 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2017 | 9957 | 0.020 |
Why?
|
| Selection, Genetic | 2 | 2004 | 914 | 0.020 |
Why?
|
| Consent Forms | 1 | 2009 | 53 | 0.020 |
Why?
|
| Bottle Feeding | 1 | 2008 | 66 | 0.020 |
Why?
|
| Alleles | 2 | 2010 | 6933 | 0.020 |
Why?
|
| Socioeconomic Factors | 2 | 2013 | 7785 | 0.020 |
Why?
|
| Cell Count | 1 | 2013 | 1856 | 0.020 |
Why?
|
| Cough | 1 | 1992 | 555 | 0.020 |
Why?
|
| Lead | 1 | 1994 | 852 | 0.020 |
Why?
|
| Medical Record Linkage | 1 | 2010 | 284 | 0.020 |
Why?
|
| Aerosols | 1 | 1991 | 625 | 0.020 |
Why?
|
| Radiography, Thoracic | 1 | 1994 | 1265 | 0.020 |
Why?
|
| Models, Immunological | 1 | 2010 | 527 | 0.020 |
Why?
|
| Fractures, Bone | 1 | 2020 | 1947 | 0.020 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2012 | 567 | 0.020 |
Why?
|
| Jamaica | 1 | 2007 | 51 | 0.020 |
Why?
|
| Triage | 1 | 1994 | 977 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2011 | 1799 | 0.020 |
Why?
|
| Caribbean Region | 1 | 2007 | 194 | 0.020 |
Why?
|
| Pregnancy Complications | 1 | 2001 | 2861 | 0.020 |
Why?
|
| Kidney Failure, Chronic | 1 | 2020 | 2535 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2001 | 3338 | 0.020 |
Why?
|
| Echocardiography | 1 | 1999 | 5099 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2010 | 4479 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2014 | 2308 | 0.020 |
Why?
|
| Antipsychotic Agents | 1 | 1979 | 3057 | 0.020 |
Why?
|
| Poisson Distribution | 1 | 2007 | 513 | 0.020 |
Why?
|
| Interviews as Topic | 2 | 2003 | 2539 | 0.020 |
Why?
|
| Health Promotion | 1 | 2017 | 2205 | 0.020 |
Why?
|
| Caregivers | 1 | 2017 | 2095 | 0.020 |
Why?
|
| Language | 1 | 2014 | 1471 | 0.020 |
Why?
|
| HLA-A3 Antigen | 1 | 2004 | 34 | 0.020 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2009 | 841 | 0.020 |
Why?
|
| Georgia | 1 | 2005 | 186 | 0.020 |
Why?
|
| Virology | 1 | 2005 | 77 | 0.020 |
Why?
|
| Linear Models | 3 | 2003 | 5952 | 0.020 |
Why?
|
| Health Personnel | 2 | 2011 | 3219 | 0.020 |
Why?
|
| Survivors | 1 | 1995 | 2291 | 0.020 |
Why?
|
| Amino Acids | 1 | 2010 | 1737 | 0.020 |
Why?
|
| Dyspnea | 1 | 1992 | 1303 | 0.010 |
Why?
|
| Temperance | 1 | 2004 | 89 | 0.010 |
Why?
|
| Haplotypes | 1 | 2010 | 2779 | 0.010 |
Why?
|
| Aging | 1 | 2023 | 8663 | 0.010 |
Why?
|
| Sequence Analysis, RNA | 1 | 2012 | 2012 | 0.010 |
Why?
|
| Review Literature as Topic | 1 | 2006 | 336 | 0.010 |
Why?
|
| Chickenpox Vaccine | 1 | 2003 | 79 | 0.010 |
Why?
|
| HIV Protease | 1 | 2003 | 96 | 0.010 |
Why?
|
| Investments | 1 | 2005 | 143 | 0.010 |
Why?
|
| Patient Education as Topic | 1 | 2013 | 2278 | 0.010 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 1 | 2004 | 222 | 0.010 |
Why?
|
| Immunodominant Epitopes | 1 | 2004 | 267 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2011 | 5181 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2011 | 3207 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2010 | 4010 | 0.010 |
Why?
|
| Body Constitution | 1 | 2002 | 278 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2012 | 5974 | 0.010 |
Why?
|
| Meta-Analysis as Topic | 1 | 2006 | 1343 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 2004 | 18111 | 0.010 |
Why?
|
| Attitude of Health Personnel | 1 | 1994 | 3842 | 0.010 |
Why?
|
| Pregnancy Outcome | 1 | 2011 | 2795 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2010 | 5451 | 0.010 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2004 | 880 | 0.010 |
Why?
|
| Acute Disease | 1 | 2011 | 7147 | 0.010 |
Why?
|
| Mesoridazine | 1 | 1979 | 2 | 0.010 |
Why?
|
| Drug Hypersensitivity | 1 | 2008 | 884 | 0.010 |
Why?
|
| Hydroxylation | 1 | 1979 | 141 | 0.010 |
Why?
|
| Chlorpromazine | 1 | 1979 | 111 | 0.010 |
Why?
|
| Immunity, Innate | 1 | 2010 | 2962 | 0.010 |
Why?
|
| Point Mutation | 1 | 2003 | 1624 | 0.010 |
Why?
|
| Social Class | 1 | 2007 | 1997 | 0.010 |
Why?
|
| Self Efficacy | 1 | 2002 | 616 | 0.010 |
Why?
|
| Severity of Illness Index | 2 | 2007 | 15535 | 0.010 |
Why?
|
| Medicare | 1 | 1994 | 6566 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2014 | 12720 | 0.010 |
Why?
|
| Phylogeny | 1 | 2003 | 2804 | 0.010 |
Why?
|
| Infection Control Practitioners | 1 | 1995 | 12 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2006 | 5077 | 0.010 |
Why?
|
| United States Public Health Service | 1 | 1995 | 31 | 0.010 |
Why?
|
| Dyslexia, Acquired | 1 | 1995 | 14 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2000 | 1460 | 0.010 |
Why?
|
| Myocardial Revascularization | 1 | 1999 | 841 | 0.010 |
Why?
|
| Penicillamine | 1 | 1995 | 59 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2013 | 5749 | 0.010 |
Why?
|
| Matched-Pair Analysis | 1 | 1994 | 288 | 0.010 |
Why?
|
| Hypertension | 1 | 2013 | 8479 | 0.010 |
Why?
|
| Body Composition | 1 | 2002 | 2402 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2004 | 13814 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2003 | 4805 | 0.010 |
Why?
|
| Base Sequence | 1 | 2003 | 12797 | 0.010 |
Why?
|
| Length of Stay | 1 | 2005 | 6311 | 0.010 |
Why?
|
| Education | 1 | 1995 | 543 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2010 | 12262 | 0.010 |
Why?
|
| Disease Outbreaks | 1 | 2001 | 1771 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2010 | 15520 | 0.010 |
Why?
|
| Adipose Tissue | 1 | 2002 | 3280 | 0.010 |
Why?
|
| Protein Binding | 1 | 1979 | 9384 | 0.000 |
Why?
|
| Life Style | 1 | 1998 | 3835 | 0.000 |
Why?
|
| Mutation | 1 | 2009 | 29786 | 0.000 |
Why?
|
| Societies, Medical | 1 | 1995 | 3743 | 0.000 |
Why?
|
| Clinical Competence | 1 | 1994 | 4687 | 0.000 |
Why?
|
| Myocardial Infarction | 1 | 1999 | 11718 | 0.000 |
Why?
|
| Animals | 1 | 2004 | 168770 | 0.000 |
Why?
|